Rafferty Asset Management, LLC Prelude Therapeutics Inc Transaction History

Rafferty Asset Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$11.89 - $31.74 $439,169 - $1.17 Million	-36,936 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$25.78 - $38.65 $331,118 - $496,420	-12,844 Reduced 25.8%	36,936 $1.15 Million
Q2 2021 Aug 10, 2021	BUY	$28.63 - $44.3 $38,077 - $58,918	1,330 Added 2.75%	49,780 $1.43 Million
Q1 2021 May 10, 2021	BUY	$39.27 - $91.68 $1.9 Million - $4.44 Million	48,450 New	48,450 $2.1 Million

36M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $35.3M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.